ALPG His Tag Protein, Mouse,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Mouse
Synonyms	ALPG, GCAP, ALP-1, ALPPL2, PLAP-like, ALPPL, Alkaline phosphatase, germ cell type
Accession	P24823
Amino Acid Sequence	Val19-Ser502 with His Tag at C-Terminus
Expression System	HEK293
Molecular Weight	60-72kDa (Reducing)
Purity	＞95% by SDS-PAGE &＞85% by SEC-HPLC
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	His Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, PH7.4, 5% trehalose
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	Yang Su, et al. ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen. Cancer Res, 2020. Axel, et al. Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR Circuits. bioRxiv, 2021. Shuang Liu, et al. High expression of ALPPL2 is associated with poor prognosis in gastric cancer, Human Pathology, 2019. Pooja Dua, et al. Alkaline Phosphatase ALPPL-2 Is a Novel Pancreatic Carcinoma-Associated Protein. Cancer Res 2013. 5. Bi, Yan, et al. Identification of ALPPL2 as a naive pluripotent state-specific surface protein essential for human naive pluripotency regulation. Cell Reports, 2020.

Background

Alkaline phosphatase, placental-like 2 (ALPPL2, also known as ALPG) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein and a member of the human alkaline phosphatase family. Typically not expressed in normal tissues except for the trophoblast, ALPPL2 shows a high tumor specificity. Immunohistochemical (IHC) analysis of tumor tissue arrays has revealed its expression in 43% of mesotheliomas, 60% of ovarian cancers, 36% of pancreatic cancers, 18% of gastric cancers, and 100% of seminomas.
ALPPL2 is not only a candidate for therapy development targeting ALPPL2-expressing tumors but has also been identified as a significant surface marker specific to the naive state of pluripotency, which is essential for both the establishment and maintenance of this state. Studies have demonstrated that the knockout of ALPPL2 can specifically impact the establishment, stability, and maintenance of naive pluripotency, confirming that the ALPPL2 protein is a functional molecular marker of the naive state surface.